A Phase 3 interventional study of Vedolizumab and Vedolizumab placebo in Ulcerative Colitis, sponsored by Takeda. Completed at 59 sites in Japan. Open to participants aged 15 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-04-25.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 11th largest by enrollment, is one of 2 that started in 2014, is one of 14 in phase 3, and was the 5th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 15 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 292 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 17th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2014, is one of 21 in phase 3, and was the 16th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with moderate or severe ulcerative colitis (UC).
This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002 (Vedolizumab) in induction and maintenance therapy in Japanese patients with moderately or severely active ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants meeting the following treatment failure criteria with at least one of the following agents within 5 years before signing on the informed consent:
Immunomodulators (azathioprine [AZA] or 6- mercaptopurine [6-MP])
Tumor necrosis factor-alpha (TNFα) antagonist
Exclusion Criteria:
Participants having a complication or a history of However, it will not apply to the following participants;
For participants having a substantially distant history of malignancy (eg, 10 years or longer without recurrence since treatment completion), the Investigator and the sponsor will discuss to decide eligibility on the basis of type of malignancy and treatment applied.
Participants for which any of the following laboratory abnormalities were found at the screening;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab placebo-matching, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
Drug: Vedolizumab placebo
Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2, and 6 in the induction phase.
Drug: Vedolizumab
Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 in the induction phase.
Drug: Vedolizumab
Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive placebo in maintenance phase.
Drug: Vedolizumab · Drug: Vedolizumab placebo
Vedolizumab 300 mg, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
Drug: Vedolizumab
Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved clinical response at Week 10 received placebo in maintenance phase without randomization.
Drug: Vedolizumab placebo
Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 in open-label cohort.
Drug: Vedolizumab
Vedolizumab intravenous infusion
Also known as: MLN0002
Vedolizumab placebo
Percentage of Participants With a Clinical Response at Week 10 in Induction Phase
Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores (rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment), a global assessment by the physician, and an endoscopic subscore. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Week 10
Percentage of Participants With Clinical Remission at Week 60 in Maintenance Phase
Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Week 60
Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With TEAE Related to Body Weight
Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With TEAE Related to Vital Signs
Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).
Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With TEAE Related to Electrocardiogram (ECG)
Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With Markedly Abnormal Laboratory Parameters Values
The laboratory values outside the range (Hemoglobin \<=7 g/dL, Lymphocytes \<500 /µL, WBC \<2000 /µL, Platelets \<7.5 10\^4/µL, Neutrophils \<1000 /µL, alanine aminotransferase (ALT) \>3.0 U/L x upper limit of normal (ULN), aspartate aminotransferase (AST) \>3.0 U/L x ULN, Total Bilirubin \>2.0 mg/dL x ULN, Amylase \>2.0 (U/L) x ULN were considered markedly abnormal. Only laboratory parameters with events were represented.
Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Percentage of Participants With Clinical Remission at Week 10 in Induction Phase
Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Week 10
Percentage of Participants With Mucosal Healing at Week 10 in Induction Phase
Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).
Time frame: Week 10
Percentage of Participants With Durable Clinical Response in Maintenance Phase
Durable clinical response is defined as reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Weeks 10 and 60
Percentage of Participants With Mucosal Healing at Week 60 in Maintenance Phase
Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).
Time frame: Week 60
Percentage of Participants With Durable Remission in Maintenance Phase
Durable clinical remission is defined as complete Mayo score of ≤2 points and no individual subscore \>1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Weeks 10 and 60
Percentage of Participants With Corticosteroid-Free Remission at Week 60 in Maintenance Phase
Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Week 60
Serum Vedolizumab Concentration in Induction Phase
Time frame: Pre-dose at Weeks 2, 6, 10 and 14
Serum Vedolizumab Concentration in Maintenance Phase
Time frame: Pre-dose at Weeks 2, 6, 10, 14, 22, 30 and 60
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase
Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of electrochemoluminescent (ECL) assay.
Time frame: Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of ECL assay.
Time frame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase
Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.
Time frame: Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.
Time frame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Participants took part in the study at 86 investigative sites in Japan from 04 February 2014 to 28 June 2018.
| Milestone | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Started | 82 | 164 | 46 | 0 | 0 | 0 | 0 |
| Completed | 78 | 155 | 36 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 9 | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Pretreatment event/adverse event | 2 | 8 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Major protocol deviation | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 42 | 41 | 26 | 0 |
| Completed | 0 | 0 | 0 | 18 | 30 | 12 | 0 |
| Not completed | 0 | 0 | 0 | 24 | 11 | 14 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 13 | 8 | 12 | 0 |
| Withdrew: Pretreatment event/adverse event | 0 | 0 | 0 | 6 | 1 | 1 | 0 |
| Withdrew: Voluntary withdrawal | 0 | 0 | 0 | 3 | 2 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Milestone | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 259 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 188 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 71 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 44 |
| Withdrew: Pretreatment event/adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 19 |
| Withdrew: Voluntary withdrawal | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Withdrew: Major protocol deviation | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores (rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment), a global assessment by the physician, and an endoscopic subscore. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With a Clinical Response at Week 10 in Induction Phase | 32.9 (22.942 to 44.186) | 39.6 (32.093 to 47.557) |
Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission at Week 60 in Maintenance Phase | 31.0 (17.622 to 47.086) | 56.1 (39.750 to 71.531) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs) | 43 | 82 | 33 | 33 | 36 | 18 | 241 |
| Participants | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With TEAE Related to Body Weight | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).
| Participants | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With TEAE Related to Vital Signs | 2 | 5 | 3 | 2 | 2 | 0 | 24 |
| Participants | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With TEAE Related to Electrocardiogram (ECG) | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
The laboratory values outside the range (Hemoglobin \<=7 g/dL, Lymphocytes \<500 /µL, WBC \<2000 /µL, Platelets \<7.5 10\^4/µL, Neutrophils \<1000 /µL, alanine aminotransferase (ALT) \>3.0 U/L x upper limit of normal (ULN), aspartate aminotransferase (AST) \>3.0 U/L x ULN, Total Bilirubin \>2.0 mg/dL x ULN, Amylase \>2.0 (U/L) x ULN were considered markedly abnormal. Only laboratory parameters with events were represented.
| Participants | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Hemoglobin (g/dL) <=7 | 1 | 4 | 1 | 0 | 0 | 0 | 6 |
| Lymphocytes (/µL) <500 | 6 | 2 | 2 | 1 | 0 | 1 | 20 |
| White Blood Cell (WBC) (/µL) <2000 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Neutrophils (/µL) <1000 | 1 | 1 | 1 | 1 | 0 | 0 | 4 |
| Alanine Aminotransferase (ALT) (U/L) >3.0 x ULN | 1 | 0 | 0 | 1 | 0 | 0 | 4 |
| Aspartate Aminotransferase (AST) (U/L) >3.0 x ULN | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| Total Bilirubin (mg/dL) >2.0 x ULN | 0 | 2 | 0 | 0 | 0 | 0 | 1 |
| Amylase (U/L) >2.0 x ULN | 1 | 2 | 1 | 0 | 0 | 0 | 4 |
Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission at Week 10 in Induction Phase | 12.2 (6.006 to 21.286) | 18.3 (12.695 to 25.072) |
Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Mucosal Healing at Week 10 in Induction Phase | 30.5 (20.796 to 41.638) | 36.6 (29.213 to 44.452) |
Durable clinical response is defined as reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Durable Clinical Response in Maintenance Phase | 35.7 (21.551 to 51.974) | 65.9 (49.405 to 79.917) |
Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Mucosal Healing at Week 60 in Maintenance Phase | 33.3 (19.567 to 49.549) | 63.4 (46.936 to 77.877) |
Durable clinical remission is defined as complete Mayo score of ≤2 points and no individual subscore \>1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Durable Remission in Maintenance Phase | 16.7 (6.974 to 31.364) | 26.8 (14.221 to 42.944) |
Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Corticosteroid-Free Remission at Week 60 in Maintenance Phase | 20.0 (4.331 to 48.089) | 46.2 (19.223 to 74.865) |
| μg/mL | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg |
|---|---|---|
| Week 2 | 31.93 ± 9.0617 | 33.96 ± 7.7002 |
| Week 6 | 29.58 ± 12.965 | 31.53 ± 12.937 |
| Week 10 | 31.42 ± 14.462 | 36.63 ± 16.058 |
| Week 14 | 16.09 ± 7.3624 | 19.04 ± 6.6528 |
| μg/mL | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg |
|---|---|---|
| Week 2 | 32.87 ± 9.8729 | 34.92 ± 7.3732 |
| Week 6 | 32.80 ± 12.953 | 35.87 ± 11.983 |
| Week 10 | 39.21 ± 15.076 | 41.02 ± 11.955 |
| Week 14 | 16.05 ± 7.4224 | 17.31 ± 7.1914 |
| Week 22 | 2.913 ± 2.3243 | 14.45 ± 6.0327 |
| Week 30 | 0.2200 ± 0.48146 | 13.77 ± 6.3692 |
| Week 60 | 0.000 ± 0.0000 | 21.16 ± 8.9078 |
Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of electrochemoluminescent (ECL) assay.
| Participants | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg |
|---|---|---|
| Week 0 | 0 | 0 |
| Week 10 | 1 | 0 |
| 16 Weeks After Last Administration | 1 | 1 |
Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of ECL assay.
| Participants | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg |
|---|---|---|
| Week 0 | 0 | 0 |
| Week 10 | 0 | 0 |
| Week 30 | 4 | 0 |
| Week 60 | 1 | 0 |
| 16 Weeks After Last Administration | 0 | 0 |
Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.
| Participants | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg |
|---|---|---|
| Week 0 | 0 | 0 |
| Week 10 | 1 | 0 |
| 16 Weeks After Last Administration | 1 | 1 |
Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.
| Participants | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg |
|---|---|---|
| Week 0 | 0 | 0 |
| Week 10 | 0 | 0 |
| Week 30 | 3 | 0 |
| Week 60 | 0 | 0 |
| 16 Weeks After Last Administration | 0 | 0 |
Collected over From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Phase: Cohort 1, Placebo | 0/82 (0%) | 4/82 (4.9%) | 10/82 (12.2%) |
| Induction Phase: Cohort 1, Vedolizumab 300 mg | 0/164 (0%) | 10/164 (6.1%) | 28/164 (17.1%) |
| Induction Phase: Cohort 2, Vedolizumab 300 mg | 0/46 (0%) | 6/46 (13%) | 15/46 (32.6%) |
| Maintenance Phase: Placebo | 0/42 (0%) | 3/42 (7.1%) | 17/42 (40.5%) |
| Maintenance Phase: Vedolizumab 300 mg | 0/41 (0%) | 4/41 (9.8%) | 27/41 (65.9%) |
| Maintenance Phase: Placebo Continuation | 0/26 (0%) | 1/26 (3.8%) | 13/26 (50%) |
| Open-Label Cohort: Vedolizumab 300 mg | 0/259 (0%) | 48/259 (18.5%) | 191/259 (73.7%) |
| Event | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 2/82 | 6/164 | 4/46 | 2/42 | 2/41 | 0/26 | 25/259 |
| DehydrationMetabolism and nutrition disorders | 0/82 | 0/164 | 2/46 | 0/42 | 0/41 | 0/26 | 1/259 |
| Enterocolitis bacterialInfections and infestations | 0/82 | 0/164 | 0/46 | 1/42 | 0/41 | 1/26 | 0/259 |
| PyrexiaGeneral disorders | 0/82 | 0/164 | 0/46 | 0/42 | 1/41 | 0/26 | 0/259 |
| AppendicitisInfections and infestations | 0/82 | 0/164 | 0/46 | 0/42 | 1/41 | 0/26 | 2/259 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/82 | 0/164 | 0/46 | 0/42 | 1/41 | 0/26 | 0/259 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/82 | 0/164 | 0/46 | 0/42 | 1/41 | 0/26 | 0/259 |
| EndometriosisReproductive system and breast disorders | 0/82 | 0/164 | 0/46 | 1/42 | 0/41 | 0/26 | 0/259 |
| Granulomatous dermatitisSkin and subcutaneous tissue disorders | 0/82 | 0/164 | 0/46 | 1/42 | 0/41 | 0/26 | 0/259 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/82 | 0/164 | 1/46 | 0/42 | 0/41 | 0/26 | 0/259 |
| Event | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab 300 mg | Maintenance Phase: Placebo Continuation | Open-Label Cohort: Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 8/82 | 23/164 | 12/46 | 9/42 | 18/41 | 8/26 | 130/259 |
| Dental cariesGastrointestinal disorders | 0/82 | 0/164 | 0/46 | 0/42 | 4/41 | 0/26 | 0/259 |
| Colitis ulcerativeGastrointestinal disorders | 0/82 | 0/164 | 0/46 | 4/42 | 0/41 | 1/26 | 18/259 |
| InfluenzaInfections and infestations | 0/82 | 0/164 | 0/46 | 0/42 | 0/41 | 0/26 | 24/259 |
| HeadacheNervous system disorders | 2/82 | 6/164 | 3/46 | 1/42 | 2/41 | 2/26 | 23/259 |
| Back painMusculoskeletal and connective tissue disorders | 0/82 | 0/164 | 0/46 | 0/42 | 0/41 | 0/26 | 22/259 |
| White blood cell count decreasedInvestigations | 0/82 | 0/164 | 0/46 | 2/42 | 2/41 | 2/26 | 0/259 |
| Upper respiratory tract infectionInfections and infestations | 0/82 | 0/164 | 0/46 | 1/42 | 0/41 | 2/26 | 19/259 |
| HaemorrhoidsGastrointestinal disorders | 0/82 | 0/164 | 0/46 | 0/42 | 0/41 | 2/26 | 0/259 |
| VomitingGastrointestinal disorders | 0/82 | 0/164 | 0/46 | 1/42 | 3/41 | 1/26 | 0/259 |
All participants who entered in the induction phase.
| Age, Continuous(years) | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 44.0 ± 15.97 | 42.3 ± 14.42 | 42.4 ± 15.60 | 42.8 ± 15.02 |
| Sex: Female, Male(Participants) | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Female | 27 | 65 | 20 | 112 |
| Male | 55 | 99 | 26 | 180 |
| Race and Ethnicity Not Collected(Participants) | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Region of Enrollment(Participants) | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Japan | 82 | 164 | 46 | 292 |
| Weight(kg) | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 60.36 ± 12.411 | 58.58 ± 11.640 | 57.74 ± 10.559 | 58.95 ± 11.699 |
| Body Mass Index (BMI)(kg/m^2) | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 21.76 ± 3.660 | 21.72 ± 3.411 | 21.12 ± 2.714 | 21.64 ± 3.382 |
| Smoking Classification(Participants) | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Never smoked | 44 | 85 | 23 | 152 |
| Current smoker | 3 | 9 | 5 | 17 |
| Ex-smoker | 35 | 70 | 18 | 123 |
| Duration of Ulcerative Colitis (UC)(years) | Induction Phase: Cohort 1, Placebo | Induction Phase: Cohort 1, Vedolizumab 300 mg | Induction Phase: Cohort 2, Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 8.57 ± 7.973 | 7.23 ± 6.230 | 9.19 ± 7.725 | 7.91 ± 7.022 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Feb 2014 to primary completion in Feb 2018, 48 months.
Results were first posted in Mar 2019, 1 year after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 48 months is close to that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab